Focal Segmental Glomerulosclerosis research hub
8 indexed studies · 4 currently recruiting
- recruitingPHASE2
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
This study is looking at a new medicine called sparsentan for children aged 1 to 17 with certain kidney conditions like FSGS, MCD, IgAN, IgAV, and Alport Syndrome. It will check if the medicine is safe, works well, and how the body handles it over two years.
United States · Germany · Italy - recruiting
National Registry of Rare Kidney Diseases
This registry is collecting information from people with rare kidney diseases across the UK. It aims to improve understanding, create better care guidelines, and help develop new treatments for these conditions. If you have a rare kidney disease, your information could help.
United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
Vonafexor fixed dose-escalation safety and proof-of-concept study in patients with at risk of progression Alport syndrome
This study is testing a new medicine, Vonafexor, for people with Alport Syndrome, a kidney condition. Researchers want to see if the medicine is safe and if it can help slow down the disease's progress. They'll check for side effects and monitor kidney health.
Spain · France · Germany - recruitingPHASE2
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
This study is looking into a new medication called BAY 3401016 for adults with Alport Syndrome, a genetic kidney condition. It aims to see if this medicine can help slow down kidney damage by blocking a specific protein.
United States · Argentina · Canada - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A study to learn how safe the study treatment BAY3401016 is, how it affects the body and how it moves into, through, and out of the body when a single amount is given to healthy male participants
This study is looking at a new medicine called BAY3401016. It's the first time it will be given to people. Healthy men will take a single dose so doctors can check if it's safe, how it affects their bodies, and how it moves in and out of their system. This early research helps us understand more about potential new treatments for conditions like Alport syndrome.
Germany - active not recruitingPHASE2
Atrasentan in Patients With Proteinuric Glomerular Diseases
This study looks at a new medicine called atrasentan for people with certain kidney diseases. It aims to see if atrasentan can help reduce protein in the urine and protect kidney function. Different groups of patients with kidney conditions like IgA nephropathy and diabetic kidney disease are being included.
United States · Australia · Italy - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the NOX1/4 Inhibitor Setanaxib in Patients with Alport Syndrome
This study is testing a new medicine, Setanaxib, for Alport syndrome. We want to see if it's safe, how it works in the body, and if it helps reduce kidney damage and other symptoms. Half the participants will get the new medicine, and half will get a dummy pill.
Spain · Czechia · France - recruiting
Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
This study looks at how different medicines might help people with Alport syndrome, a kidney condition. It's an ongoing study that collects information from patients around the world to see if treatments can slow down kidney damage and improve health over time.
Germany